Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophrenia

RegulatoryapprovedOKEDIPositive

AI Analysis

Summary

Quebec became the first Canadian province to list OKEDI (extended-release injectable risperidone) on its public drug reimbursement formulary for schizophrenia treatment. This reimbursement approval enables wider patient access to the medication in Quebec.

Outcome Details

Listed on Quebec public drug reimbursement formulary

Importance:5/10

Sentiment:

0.70

regulatory approvalreimbursementschizophreniainjectable formulationCanada

Related Companies

$BHC

Read the original article

Published by yahoo_finance on July 6, 2026 11:00 AM

Read Original